Avinger (AVGR) Tops Q2 EPS by 7c

Avinger (NASDAQ: AVGR) reported Q2 EPS of ($0.83), $0.07 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.72 million.

Avinger sees FY2015 revenue of $12-14 million.

"I am pleased with the progress we've made in the first half of 2015 on the objectives we set for the year. We are on track to complete six-month follow-up data analysis in our VISION Trial to support a 510(k) submission for Pantheris in the second half of this year. We have also made meaningful progress towards building the infrastructure to support a broad-scale commercial launch of Pantheris in the first half of 2016," said Jeff Soinski, President and Chief Executive Officer. "During the second quarter, we saw a positive impact on our top line compared to the first quarter as we accelerated growth of our installed base of productive lumivascular accounts and increased utilization of our currently available Ocelot family of catheters, which gives physicians experience with our lumivascular system and extends awareness of the benefits of the platform."

For earnings history and earnings-related data on Avinger (AVGR) click here.

You May Also Be Interested In

• Macy's (M) stock pares premarket losses on plans to expand Nike product offering
• Cooper Cos. (COO) Tops Q2 EPS by 6c; raises guidance
• Chargepoint Holdings Inc. (CHPT) Misses Q1 EPS by 4c, Offers Guidance